Kymera Therapeutics, Inc. (KYMR)
Automate Your Wheel Strategy on KYMR
With Tiblio's Option Bot, you can configure your own wheel strategy including KYMR - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol KYMR
- Rev/Share 0.7347
- Book/Share 9.8099
- PB 3.0214
- Debt/Equity 0.1098
- CurrentRatio 8.4923
- ROIC -0.3189
- MktCap 1930144944.0
- FreeCF/Share -2.9941
- PFCF -8.0435
- PE -9.8619
- Debt/Assets 0.094
- DivYield 0
- ROE -0.3011
- Rating C-
- Score 1
- Recommendation Strong Sell
- P/E Score 1
- DCF Score 1
- P/B Score 2
- D/E Score 3
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Resumed | KYMR | Stifel | -- | Buy | -- | $55 | May 20, 2025 |
| Initiation | KYMR | Citigroup | -- | Buy | -- | $52 | March 13, 2025 |
| Initiation | KYMR | BTIG Research | -- | Buy | -- | $60 | Dec. 10, 2024 |
| Initiation | KYMR | BMO Capital Markets | -- | Market Perform | -- | $55 | Dec. 6, 2024 |
| Resumed | KYMR | Leerink Partners | -- | Outperform | -- | $60 | Sept. 9, 2024 |
| Upgrade | KYMR | Wolfe Research | Peer Perform | Outperform | -- | $65 | Aug. 26, 2024 |
News
Kymera Therapeutics Presents New Preclinical Data for KT-621, a First-In-Class, Oral STAT6 Degrader at the American Thoracic Society International Conference
Published: May 19, 2025 by: GlobeNewsWire
Sentiment: Neutral
KT-621, a potent, selective, oral STAT6 degrader, demonstrated comparable or superior activity to dupilumab in a newly disclosed preclinical chronic asthma model reversing disease progression
Read More
Kymera' s Q1 Loss Narrower Than Expected, Pipeline Progress Encouraging
Published: May 09, 2025 by: Zacks Investment Research
Sentiment: Neutral
Kymera reports a narrower-than-expected loss for the first quarter of 2025. The company expects the current cash balance to provide a runway into the first half of 2028.
Read More
Kymera Therapeutics, Inc. (KYMR) Reports Q1 Loss, Tops Revenue Estimates
Published: May 09, 2025 by: Zacks Investment Research
Sentiment: Negative
Kymera Therapeutics, Inc. (KYMR) came out with a quarterly loss of $0.82 per share versus the Zacks Consensus Estimate of a loss of $0.92. This compares to loss of $0.69 per share a year ago.
Read More
Kymera Therapeutics Expands Industry Leading Immunology Pipeline with New First-in-Class, Oral IRF5 Degrader Program with Potential to Address Multiple Immuno-Inflammatory Diseases
Published: May 09, 2025 by: GlobeNewsWire
Sentiment: Neutral
IRF5 program strengthens Kymera's oral immunology pipeline with a complementary mechanism to expand into rheumatic and other autoimmune diseases with a potential best-in-class oral drug
Read More
Kymera Therapeutics Announces First Quarter 2025 Financial Results and Provides a Business Update
Published: May 09, 2025 by: GlobeNewsWire
Sentiment: Neutral
Completed KT-621 (STAT6) SAD/MAD Phase 1 healthy volunteer trial with data to be reported in June 2025 First patient dosed in KT-621 (STAT6) BroADen Phase 1b trial in moderate to severe atopic dermatitis (AD) with data expected in 4Q25 KT-579 (IRF5) new oral immunology degrader program, with broad clinical potential in rheumatic and other autoimmune diseases, expected to enter Phase 1 clinical trial in early 2026 KT-474/SAR444656 (IRAK4) Phase 2b trials in HS and AD ongoing, led by partner Sanofi; Kymera achieved a $20 million milestone payment as part of the IRAK4 collaboration in April 2025 Strategic decision made not …
Read More
Kymera Therapeutics to Participate in Fireside Chat at the BofA Securities 2025 Health Care Conference
Published: May 07, 2025 by: GlobeNewsWire
Sentiment: Neutral
WATERTOWN, Mass., May 07, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, today announced that the Company will participate in a fireside chat at the BofA Securities 2025 Healthcare Conference in Las Vegas, NV on May 14, 2025, at 3:40 p.m. PT.
Read More
Kymera Therapeutics Announces First Patient Dosed in BROADEN Phase 1b Atopic Dermatitis Clinical Trial of KT-621, a First-in-Class Oral STAT6 Degrader
Published: April 22, 2025 by: GlobeNewsWire
Sentiment: Neutral
Data from the BroADen Phase 1b atopic dermatitis (AD) patient trial expected to be reported in 4Q25 Completed SAD/MAD dosing in KT-621 Phase 1 healthy volunteer trial with data to be reported in June 2025 Two parallel Phase 2b trials in AD and asthma planned to start in 4Q25 and 1Q26, respectively WATERTOWN, Mass., April 22, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, today announced that it recently initiated dosing in its BroADen Phase 1b clinical trial evaluating KT-621, an oral, …
Read More
Kymera's Q4 Loss Wider Than Expected, Pipeline in Focus
Published: February 28, 2025 by: Zacks Investment Research
Sentiment: Negative
KYMR reports a wider-than-expected loss for the fourth quarter of 2024. The company expects the current cash balance to provide a runway into mid-2027.
Read More
Kymera Therapeutics, Inc. (KYMR) Q4 2024 Earnings Call Transcript
Published: February 27, 2025 by: Seeking Alpha
Sentiment: Neutral
Kymera Therapeutics, Inc. (NASDAQ:KYMR ) Q4 2024 Earnings Conference Call February 27, 2025 8:30 AM ET Company Participants Justine Koenigsberg - Vice President-Investor Relations Nello Mainolfi - Founder, President & Chief Executive Officer Jared Gollob - Chief Medical Officer Bruce Jacobs - Chief Financial Officer Conference Call Participants Faisal Khurshid - Leerink Partners Andy Chen - Wolfe Research Paul Jeng - Guggenheim Ron Feiner - JPMorgan Jeff Jones - Oppenheimer Brad Canino - Stifel Marc Frahm - TD Cowen Ellie Merle - UBS Securities Parth Patel - Morgan Stanley Kripa Devarakonda - Truist Securities Eva Fortea-Verdejo - Wells Fargo Eric …
Read More
Kymera Therapeutics to Participate in Upcoming March Investor Conferences
Published: February 26, 2025 by: GlobeNewsWire
Sentiment: Neutral
WATERTOWN, Mass., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, today announced that the Company will participate in fireside chats at the following upcoming investor events:
Read More
About Kymera Therapeutics, Inc. (KYMR)
- IPO Date 2020-08-21
- Website https://www.kymeratx.com
- Industry Biotechnology
- CEO Dr. Nello Mainolfi M.D., Ph.D.
- Employees 208